Compounds and related methods for treatment of neurodegenerative diseases

Abstract

Aspects of the invention pertain to chemical compounds, therapeutic compositions, and methods for treating neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau.

We claim: 
     
         1 . A method of reducing intracellular tau phosphorylation levels, wherein the method comprises administering, to cells comprising phosphorylated protein tau, an effective amount of compound B: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The method according to  claim 1 , wherein the cells are in a subject in need of treatment for a neurodegenerative disease. 
     
     
         3 . The method of  claim 2 , wherein the neurodegenerative disease is a tauopathy. 
     
     
         4 . The method of  claim 3 , wherein the subject is a human. 
     
     
         5 . The method of  claim 4 , wherein the neurodegenerative disease is selected from Alzheimer's disease, Parkinson's disease, frontotemporal dementia, frontotemporal dementia with Parkinsonism, frontotemporal lobe dementia, pallidopontonigral degeneration, progressive supranuclear palsy, multiple system tauopathy, multiple system tauopathy with presenile dementia, Wilhelmsen-Lynch disease, Pick's disease, or Pick's disease-like dementia. 
     
     
         6 . The method of  claim 4 , wherein the neurodegenerative disease is Alzheimer's disease. 
     
     
         7 . A pharmaceutical composition comprising a therapeutically effective amount of a compound selected from compound A 
       
         
           
           
               
               
           
         
         compound B 
       
       
         
           
           
               
               
           
         
         and combinations thereof; and
 a pharmaceutically acceptable carrier or adjuvant.